2026-01-04 - Analysis Report
Okay, here's a breakdown of the data provided for Eli Lilly and Co (LLY), followed by a comprehensive analysis:

**1) Return Rate Comparison:**

*   **LLY Overview:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.
*   **LLY Cumulative Return:** 281.68%
*   **VOO (S&P 500) Cumulative Return:** 91.00%
*   **Divergence:** The divergence in cumulative return between LLY and VOO is currently 190.7%, with a relative divergence of 83.9%. This means LLY has significantly outperformed the S&P 500, and the current divergence is near the higher end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2016-2018  | 37.0%   | 14.3% | 33.0%  | 0.7  | 103.7  |
| 2017-2019  | 36.0%   | 14.7% | 19.0%  | 0.7  | 117.8  |
| 2018-2020  | 30.0%   | 20.9% | 10.0%  | 0.7  | 151.4  |
| 2019-2021  | 49.0%   | 20.9% | 5.0%   | 0.7  | 247.6  |
| 2020-2022  | 59.0%   | 20.9% | 60.0%  | 0.7  | 328.0  |
| 2021-2023  | 116.0%  | 18.0% | 115.0% | 0.5  | 522.6  |
| 2022-2024  | 123.0%  | 27.0% | 104.0% | 0.6  | 692.1  |
| 2023-2025  | 183.0%  | 29.9% | 121.0% | 0.7  | 963.4  |

*   **CAGR (Compound Annual Growth Rate):** Shows the average annual growth rate over the period.  CAGR has been consistently strong, especially in recent periods (2021-2025).
*   **MDD (Maximum Drawdown):**  Represents the largest peak-to-trough decline during the period.  Drawdowns have been relatively controlled considering the high growth.
*   **Alpha:** Measures the excess return compared to the benchmark (S&P 500), adjusted for risk.  LLY has consistently generated significant alpha, indicating strong outperformance above what would be expected given its beta.
*   **Beta:** Measures the stock's volatility relative to the market.  A beta of around 0.7 suggests LLY is less volatile than the market as a whole.
*   **Cap(B):**  Shows the market capitalization in billions.  Demonstrates substantial growth in LLY's market cap over time.

**Analysis:**  This data indicates that LLY has provided significant returns while exhibiting lower volatility than the overall market. The high alpha values suggest that the company's performance is driven by factors specific to LLY, rather than simply market trends. The increasing market cap supports the narrative of a rapidly growing and successful company.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 1080.36
*   **Previous Close:** 1074.68
*   **Change:** 0.53
*   **5-day SMA:** 1078.254
*   **20-day SMA:** 1046.905
*   **60-day SMA:** 968.3677

**Analysis:** The stock is trading above all its moving averages (5-day, 20-day, and 60-day), indicating an upward trend. The 5-day SMA being close to the current price suggests recent stability, while the 20-day and 60-day SMAs being lower point to a sustained uptrend over the past few months.

**3) Indicator Analysis:**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommendation)
*   **RSI (Relative Strength Index):** 76.97
*   **PPO (Percentage Price Oscillator):** -0.1559
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** 0.6 (+): Short-term increase
*   **Expected Return (%):** 47.3%

**Analysis:**

*   **MRI:** A value of 0.8 suggests a medium investment recommendation.
*   **RSI:** An RSI of 76.97 is nearing overbought territory (typically above 70), suggesting the stock may be due for a correction or consolidation.
*   **PPO:** A slightly negative PPO suggests the short-term moving average is marginally below the long-term moving average.
*   **Hybrid Signal:** The signal suggests a "Buy" based on its risk assessment, which conflicts slightly with the high RSI.
*   **Recent Relative Divergence Change:** Indicates recent positive movement in relation to its comparison.
*   **Expected Return:** The high expected return of 47.3% is a strong positive signal.

**4) Recent News & Significant Events:**

*   **[2025-12-22] Jim Cramer Says Eli Lilly’s GLP-1 Pill Is “Going to Revolutionize Everything”**: Positive media coverage highlighting the potential of LLY's GLP-1 pill.
*   **[2025-12-29] Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs**:  Focuses on the company's obesity drug portfolio and related market dynamics.
*   **[2025-12-31] Futures Fall; Seven Stocks Near Buy Points As 2026 Looms**: LLY being mentioned as a stock near a buy point suggests it's being viewed favorably by analysts.
*   **[2026-01-03] Eli Lilly and Company $LLY Shares Purchased by CMH Wealth Management LLC**: Institutional investment signals confidence in the company's future.
*   **[2025-12-16] Where Will Eli Lilly Be in 10 Years?**:  A long-term outlook piece suggesting continued growth potential.
*   **[2025-12-26] Eli Lilly (LLY) a Top Stock Split Candidate in 2026**:  Indicates strong stock performance and potential for increased accessibility to investors.

**Analysis:** The recent news is overwhelmingly positive, focusing on the potential of LLY's GLP-1 pill, its overall position in the obesity drug market, institutional investment, and potential for a stock split. This positive sentiment is likely contributing to the stock's upward momentum.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.70)
*   **Opinions:** 27
*   **Target Price (avg/high/low):** 1093.22 / 1500.00 / 770.00

**Analysis:** The analyst consensus is a "Buy" with a relatively high average target price (1093.22) compared to the current price (1080.36).  The high target price of 1500.00 shows some analysts are very bullish.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-30 | 6.22 | 17.60 B$   |
| 2025-08-07 | 6.3  | 15.56 B$   |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2025-10-30 | 1.08 | 11.44 B$   |

**Analysis:**  Both EPS (Earnings Per Share) and Revenue have shown significant growth over the past few quarters, with a notable increase in EPS in the most recent quarters (6.22 and 6.3).  This indicates strong financial performance.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B    | 82.91%        |
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
|--------------|------------|---------|
| 2025-09-30   | $23.79B    | 23.46%  |
| 2025-06-30   | $18.27B    | 30.98%  |
| 2025-03-31   | $15.76B    | 17.50%  |
| 2024-12-31   | $14.19B    | 31.07%  |
| 2024-09-30   | $14.24B    | 6.81%   |

**Analysis:**

*   **Revenue and Profitability:**  Revenue has been consistently increasing, and the profit margin remains very high (above 80%), indicating strong operational efficiency.
*   **Capital and Profitability:**  Equity has been growing, and ROE (Return on Equity) is generally high, demonstrating efficient use of shareholder equity to generate profits.

**7) Comprehensive Analysis (Summary):**

Eli Lilly (LLY) is exhibiting strong financial performance and positive market sentiment. Here's a summary of key takeaways:

*   **Outperformance:** LLY has significantly outperformed the S&P 500, driven by factors specific to the company (high alpha).
*   **Strong Financials:**  Revenue, EPS, and profit margins are all increasing, indicating a healthy and growing business.
*   **Positive News:** Recent news is overwhelmingly positive, driven by the potential of its GLP-1 pill and increased market awareness of the obesity drugs.
*   **Analyst Confidence:** Analyst consensus is a "Buy" with an average target price higher than the current price.
*   **Technical Indicators:** While the RSI suggests the stock may be nearing overbought territory, the MRI still suggests a medium level of investment appropriateness. The upward trend is clear from moving averages.
*   **Expected Return:** Expected return is very high.

**Overall Conclusion:**

Based on the available data, Eli Lilly appears to be a strong investment opportunity. The company is experiencing robust growth, generating high profits, and benefiting from positive market sentiment and analyst outlook. While the high RSI warrants caution regarding a potential short-term correction, the long-term prospects for LLY appear very promising. The buzz around their weight-loss drugs is clearly having a positive impact. The company's fundamentals are strong, and the technical indicators suggest continued upward momentum.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.